Research programme: cancer therapeutics - BeiGene
Alternative Names: BGB-108; Brodomain containing protein 4 inhibitors - BeiGene; EGFR T790 mutation inhibitors - BeiGene; iOnc monoclonal antibody - BeiGene; iONC small molecule therapeutic - BeiGene; KRAS protein inhibitors - BeiGene; PD-1 monoclonal antibody - BeiGene; PD-L1 monoclonal antibody - BeiGeneLatest Information Update: 28 Dec 2018
At a glance
- Originator BeiGene
- Class Antineoplastics; Monoclonal antibodies; Small molecules
- Mechanism of Action BRD4 protein inhibitors; Epidermal growth factor inhibitors; HAVCR2 protein modulators; Immunomodulators; KRAS protein inhibitors; Programmed cell death 1 receptor modulators; Programmed cell death-1 ligand-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer